Myriad(US:MYGN)2025-02-24 21:26Revenue Projections - Fourth quarter 2024 total revenues are expected to be between $209 million and $211 million, representing an increase of approximately 6% to 7% compared to Q4 2023[4]. - Full year 2024 total revenues are projected to be between $836 million and $838 million, reflecting an increase of approximately 11% compared to full year 2023[4]. - For full year 2025, revenue guidance is set at $840 million to $860 million, indicating an increase of approximately 0% to 3% compared to preliminary 2024 revenue[9]. Earnings Per Share - Fourth quarter 2024 GAAP diluted loss per share is expected to be between $(0.72) and $(0.62), while adjusted diluted EPS is projected to be between $0.03 and $0.04[4]. - Full year 2024 GAAP loss per share is anticipated to be between $(1.66) and $(1.56), with adjusted EPS expected to be between $0.14 and $0.15[4]. - Full year 2025 adjusted EPS is anticipated to be between $0.07 and $0.11, based on a share count of 94 million[10]. Cash and Assets - As of December 31, 2024, cash and cash equivalents were approximately $102 million, an increase of $2 million from the end of Q3 2024[4]. Adjusted EBITDA and Net Loss - Adjusted EBITDA for the three months ended December 31, 2024, is projected to be between $10.0 million and $10.9 million, while for the twelve months, it is expected to be between $39.9 million and $40.8 million[23]. - The net loss for the three months ended December 31, 2024, is estimated to be between $65.7 million and $56.8 million, and for the twelve months, it is projected to be between $150.5 million and $141.6 million[23]. Impairment and Expenses - Goodwill and long-lived asset impairment charges for the three months ended December 31, 2024, are expected to be between $45.0 million and $41.0 million, and for the twelve months, between $58.8 million and $54.8 million[23]. - Equity compensation expenses for the twelve months ended December 31, 2024, are projected to be $49.8 million[23]. - Real estate optimization costs for the three months ended December 31, 2024, are estimated at $1.7 million, and for the twelve months, at $7.2 million[23]. - Transformation initiatives costs for the twelve months ended December 31, 2024, are expected to be $6.6 million[23]. Tax Adjustments - Tax adjustments include a tax expense (benefit) due to non-GAAP adjustments and differences in stock compensation deductions[26]. Future Financial Reporting - The company plans to release actual financial results for Q4 and full year 2024 during its earnings call in February 2025[5]. Significant Financial Factors - The impairment of acquired technology intangible assets related to the GeneSight Test is a significant factor in the financial adjustments for the year[25]. - The company is undergoing real estate initiatives, including the build-out of new laboratories in Salt Lake City and South Francisco[25].